Observational studyJournal of clinical oncology : official journal of the American Society of Clinical Oncology2018
Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer.
Open access · greenAbstract readMulticenter StudyObservational Study
In one paragraph
Observational study in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
9.8field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 97 citations in OpenAlex.
- The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials.Archives of gynecology and obstetrics · 2021Pooled it
- Pilot Trial of Streamlined Genetic Education and Traceback Genetic Testing in Prostate Cancer Survivors.Journal of the National Comprehensive Cancer Network : JNCCN · 2023Trial
- Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Trial
- Mainstream and fast-track genetic testing in pancreatic cancer patients and its impact on treatment: our experience in a tertiary hospital in Spain.Familial cancer · 2026Observational
- Association of homologous recombination repair gene mutation with clinical prognosis in histological subtypes of epithelial ovarian cancer patients.Journal of gynecologic oncology · 2026Article
- Adapting mainstreaming genetic education and clinical communication materials for cancer patients of varying backgrounds.Patient education and counseling · 2026Article
- Breast cancer specialists' experiences and attitudes towards mainstream genetic testing for patients with breast cancer.Hereditary cancer in clinical practice · 2026Article
- Experience of urologists, oncologists and nurse practitioners with mainstream genetic testing in metastatic prostate cancer.Prostate cancer and prostatic diseases · 2025Article
- Integration of Germline Genetic Testing Into Routine Clinical Practice for Patients With Pancreatic Adenocarcinoma.JCO oncology practice · 2025Article
- Impacts of BRCA mutations and clinical factors on niraparib efficacy in patients with platinum-sensitive recurrent ovarian cancer: a retrospective study.American journal of cancer research · 2025Article
- Pilot implementation study of a default genetic referral process for patients with early-onset colorectal cancer.Genetics in medicine open · 2025Article
- Patient decisions regarding cancer gene panel testing: An exploratory study.Journal of genetic counseling · 2024Article
- Implications of genetic testing and informed consent before and after genetic testing in individuals with cancer.World journal of clinical oncology · 2024Article
- ItaLynch: an ongoing Italian study to evaluate the feasibility of mainstreaming the diagnosis of Lynch syndrome in colorectal cancer patients.ESMO gastrointestinal oncology · 2024Article
- Preparing for the unexpected: Recommendations for returning secondary findings in late-stage cancer care.Genetics in medicine : official journal of the American College of Medical Genetics · 2024Article
- Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus.Journal of gynecologic oncology · 2023Article
- Clinical risk management of breast, ovarian, pancreatic, and prostatic cancers for BRCA1/2 variant carriers in Japan.Journal of human genetics · 2023Review
- Surgical Oncologists and Nurses in Breast Cancer Care are Ready to Provide Pre-Test Genetic Counseling.Annals of surgical oncology · 2023Article
- Nationwide Trends and Determinants of Germline BRCA1/2 Testing in Patients With Breast and Ovarian Cancer.Journal of the National Comprehensive Cancer Network : JNCCN · 2023Article
- Prevalence and clinical implications of germline mutations among Jordanian patients with ovarian cancer. The Jordanian exploratory cancer genetics (Jo-ECAG) ovarian study.Molecular genetics & genomic medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 1 country.
Nicoletta ColomboNicoletta Colombo, University of Milan-Bicocca; Nicoletta Colombo, Istituto Europeo di Oncologia, Milan; Giovanni Scambia, Università Cattolica del Sacro Cuore di Roma, Rome; Sandro Pignata, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G Pascale IRCCS, Naples, Italy; Gloria Huang, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx; Eva Chalas, Winthrop University Hospital, Mineola, NY; James Fiorica, Sarasota Memorial Hospital, Sarasota, FL; Linda Van Le, University of North Carolina School of Medicine, Chapel Hill, NC; Sharad Ghamande, The Georgia Cancer Center at Augusta University, Augusta; Andrew Green, Northeast Georgia Medical Center, Gainesville, GA; Santiago González-Santiago, Hospital San Pedro de Alcántara, Cáceres; Isabel Bover, Hospital Son Llàtzer, Palma; Begoña Graña Suárez, University Hospital A Coruña, Sergas, Spain; Philippe Huot-Marchand and Yann Bourhis, Mapi Real World Evidence, Lyon, France; Sudeep Karve, AstraZeneca, Gaithersburg, MD; and Christopher Blakeley, AstraZeneca, Cambridge, United Kingdom.
Gloria HuangNicoletta Colombo, University of Milan-Bicocca; Nicoletta Colombo, Istituto Europeo di Oncologia, Milan; Giovanni Scambia, Università Cattolica del Sacro Cuore di Roma, Rome; Sandro Pignata, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G Pascale IRCCS, Naples, Italy; Gloria Huang, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx; Eva Chalas, Winthrop University Hospital, Mineola, NY; James Fiorica, Sarasota Memorial Hospital, Sarasota, FL; Linda Van Le, University of North Carolina School of Medicine, Chapel Hill, NC; Sharad Ghamande, The Georgia Cancer Center at Augusta University, Augusta; Andrew Green, Northeast Georgia Medical Center, Gainesville, GA; Santiago González-Santiago, Hospital San Pedro de Alcántara, Cáceres; Isabel Bover, Hospital Son Llàtzer, Palma; Begoña Graña Suárez, University Hospital A Coruña, Sergas, Spain; Philippe Huot-Marchand and Yann Bourhis, Mapi Real World Evidence, Lyon, France; Sudeep Karve, AstraZeneca, Gaithersburg, MD; and Christopher Blakeley, AstraZeneca, Cambridge, United Kingdom.
Giovanni ScambiaNicoletta Colombo, University of Milan-Bicocca; Nicoletta Colombo, Istituto Europeo di Oncologia, Milan; Giovanni Scambia, Università Cattolica del Sacro Cuore di Roma, Rome; Sandro Pignata, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G Pascale IRCCS, Naples, Italy; Gloria Huang, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx; Eva Chalas, Winthrop University Hospital, Mineola, NY; James Fiorica, Sarasota Memorial Hospital, Sarasota, FL; Linda Van Le, University of North Carolina School of Medicine, Chapel Hill, NC; Sharad Ghamande, The Georgia Cancer Center at Augusta University, Augusta; Andrew Green, Northeast Georgia Medical Center, Gainesville, GA; Santiago González-Santiago, Hospital San Pedro de Alcántara, Cáceres; Isabel Bover, Hospital Son Llàtzer, Palma; Begoña Graña Suárez, University Hospital A Coruña, Sergas, Spain; Philippe Huot-Marchand and Yann Bourhis, Mapi Real World Evidence, Lyon, France; Sudeep Karve, AstraZeneca, Gaithersburg, MD; and Christopher Blakeley, AstraZeneca, Cambridge, United Kingdom.
Eva ChalasNicoletta Colombo, University of Milan-Bicocca; Nicoletta Colombo, Istituto Europeo di Oncologia, Milan; Giovanni Scambia, Università Cattolica del Sacro Cuore di Roma, Rome; Sandro Pignata, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G Pascale IRCCS, Naples, Italy; Gloria Huang, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx; Eva Chalas, Winthrop University Hospital, Mineola, NY; James Fiorica, Sarasota Memorial Hospital, Sarasota, FL; Linda Van Le, University of North Carolina School of Medicine, Chapel Hill, NC; Sharad Ghamande, The Georgia Cancer Center at Augusta University, Augusta; Andrew Green, Northeast Georgia Medical Center, Gainesville, GA; Santiago González-Santiago, Hospital San Pedro de Alcántara, Cáceres; Isabel Bover, Hospital Son Llàtzer, Palma; Begoña Graña Suárez, University Hospital A Coruña, Sergas, Spain; Philippe Huot-Marchand and Yann Bourhis, Mapi Real World Evidence, Lyon, France; Sudeep Karve, AstraZeneca, Gaithersburg, MD; and Christopher Blakeley, AstraZeneca, Cambridge, United Kingdom.
Sandro PignataNicoletta Colombo, University of Milan-Bicocca; Nicoletta Colombo, Istituto Europeo di Oncologia, Milan; Giovanni Scambia, Università Cattolica del Sacro Cuore di Roma, Rome; Sandro Pignata, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G Pascale IRCCS, Naples, Italy; Gloria Huang, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx; Eva Chalas, Winthrop University Hospital, Mineola, NY; James Fiorica, Sarasota Memorial Hospital, Sarasota, FL; Linda Van Le, University of North Carolina School of Medicine, Chapel Hill, NC; Sharad Ghamande, The Georgia Cancer Center at Augusta University, Augusta; Andrew Green, Northeast Georgia Medical Center, Gainesville, GA; Santiago González-Santiago, Hospital San Pedro de Alcántara, Cáceres; Isabel Bover, Hospital Son Llàtzer, Palma; Begoña Graña Suárez, University Hospital A Coruña, Sergas, Spain; Philippe Huot-Marchand and Yann Bourhis, Mapi Real World Evidence, Lyon, France; Sudeep Karve, AstraZeneca, Gaithersburg, MD; and Christopher Blakeley, AstraZeneca, Cambridge, United Kingdom.
James FioricaNicoletta Colombo, University of Milan-Bicocca; Nicoletta Colombo, Istituto Europeo di Oncologia, Milan; Giovanni Scambia, Università Cattolica del Sacro Cuore di Roma, Rome; Sandro Pignata, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G Pascale IRCCS, Naples, Italy; Gloria Huang, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx; Eva Chalas, Winthrop University Hospital, Mineola, NY; James Fiorica, Sarasota Memorial Hospital, Sarasota, FL; Linda Van Le, University of North Carolina School of Medicine, Chapel Hill, NC; Sharad Ghamande, The Georgia Cancer Center at Augusta University, Augusta; Andrew Green, Northeast Georgia Medical Center, Gainesville, GA; Santiago González-Santiago, Hospital San Pedro de Alcántara, Cáceres; Isabel Bover, Hospital Son Llàtzer, Palma; Begoña Graña Suárez, University Hospital A Coruña, Sergas, Spain; Philippe Huot-Marchand and Yann Bourhis, Mapi Real World Evidence, Lyon, France; Sudeep Karve, AstraZeneca, Gaithersburg, MD; and Christopher Blakeley, AstraZeneca, Cambridge, United Kingdom.
Linda Van LeNicoletta Colombo, University of Milan-Bicocca; Nicoletta Colombo, Istituto Europeo di Oncologia, Milan; Giovanni Scambia, Università Cattolica del Sacro Cuore di Roma, Rome; Sandro Pignata, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G Pascale IRCCS, Naples, Italy; Gloria Huang, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx; Eva Chalas, Winthrop University Hospital, Mineola, NY; James Fiorica, Sarasota Memorial Hospital, Sarasota, FL; Linda Van Le, University of North Carolina School of Medicine, Chapel Hill, NC; Sharad Ghamande, The Georgia Cancer Center at Augusta University, Augusta; Andrew Green, Northeast Georgia Medical Center, Gainesville, GA; Santiago González-Santiago, Hospital San Pedro de Alcántara, Cáceres; Isabel Bover, Hospital Son Llàtzer, Palma; Begoña Graña Suárez, University Hospital A Coruña, Sergas, Spain; Philippe Huot-Marchand and Yann Bourhis, Mapi Real World Evidence, Lyon, France; Sudeep Karve, AstraZeneca, Gaithersburg, MD; and Christopher Blakeley, AstraZeneca, Cambridge, United Kingdom.
Sharad GhamandeNicoletta Colombo, University of Milan-Bicocca; Nicoletta Colombo, Istituto Europeo di Oncologia, Milan; Giovanni Scambia, Università Cattolica del Sacro Cuore di Roma, Rome; Sandro Pignata, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G Pascale IRCCS, Naples, Italy; Gloria Huang, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx; Eva Chalas, Winthrop University Hospital, Mineola, NY; James Fiorica, Sarasota Memorial Hospital, Sarasota, FL; Linda Van Le, University of North Carolina School of Medicine, Chapel Hill, NC; Sharad Ghamande, The Georgia Cancer Center at Augusta University, Augusta; Andrew Green, Northeast Georgia Medical Center, Gainesville, GA; Santiago González-Santiago, Hospital San Pedro de Alcántara, Cáceres; Isabel Bover, Hospital Son Llàtzer, Palma; Begoña Graña Suárez, University Hospital A Coruña, Sergas, Spain; Philippe Huot-Marchand and Yann Bourhis, Mapi Real World Evidence, Lyon, France; Sudeep Karve, AstraZeneca, Gaithersburg, MD; and Christopher Blakeley, AstraZeneca, Cambridge, United Kingdom.
Santiago González-SantiagoNicoletta Colombo, University of Milan-Bicocca; Nicoletta Colombo, Istituto Europeo di Oncologia, Milan; Giovanni Scambia, Università Cattolica del Sacro Cuore di Roma, Rome; Sandro Pignata, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G Pascale IRCCS, Naples, Italy; Gloria Huang, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx; Eva Chalas, Winthrop University Hospital, Mineola, NY; James Fiorica, Sarasota Memorial Hospital, Sarasota, FL; Linda Van Le, University of North Carolina School of Medicine, Chapel Hill, NC; Sharad Ghamande, The Georgia Cancer Center at Augusta University, Augusta; Andrew Green, Northeast Georgia Medical Center, Gainesville, GA; Santiago González-Santiago, Hospital San Pedro de Alcántara, Cáceres; Isabel Bover, Hospital Son Llàtzer, Palma; Begoña Graña Suárez, University Hospital A Coruña, Sergas, Spain; Philippe Huot-Marchand and Yann Bourhis, Mapi Real World Evidence, Lyon, France; Sudeep Karve, AstraZeneca, Gaithersburg, MD; and Christopher Blakeley, AstraZeneca, Cambridge, United Kingdom.
Isabel BoverNicoletta Colombo, University of Milan-Bicocca; Nicoletta Colombo, Istituto Europeo di Oncologia, Milan; Giovanni Scambia, Università Cattolica del Sacro Cuore di Roma, Rome; Sandro Pignata, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G Pascale IRCCS, Naples, Italy; Gloria Huang, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx; Eva Chalas, Winthrop University Hospital, Mineola, NY; James Fiorica, Sarasota Memorial Hospital, Sarasota, FL; Linda Van Le, University of North Carolina School of Medicine, Chapel Hill, NC; Sharad Ghamande, The Georgia Cancer Center at Augusta University, Augusta; Andrew Green, Northeast Georgia Medical Center, Gainesville, GA; Santiago González-Santiago, Hospital San Pedro de Alcántara, Cáceres; Isabel Bover, Hospital Son Llàtzer, Palma; Begoña Graña Suárez, University Hospital A Coruña, Sergas, Spain; Philippe Huot-Marchand and Yann Bourhis, Mapi Real World Evidence, Lyon, France; Sudeep Karve, AstraZeneca, Gaithersburg, MD; and Christopher Blakeley, AstraZeneca, Cambridge, United Kingdom.
Begoña Graña SuárezNicoletta Colombo, University of Milan-Bicocca; Nicoletta Colombo, Istituto Europeo di Oncologia, Milan; Giovanni Scambia, Università Cattolica del Sacro Cuore di Roma, Rome; Sandro Pignata, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G Pascale IRCCS, Naples, Italy; Gloria Huang, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx; Eva Chalas, Winthrop University Hospital, Mineola, NY; James Fiorica, Sarasota Memorial Hospital, Sarasota, FL; Linda Van Le, University of North Carolina School of Medicine, Chapel Hill, NC; Sharad Ghamande, The Georgia Cancer Center at Augusta University, Augusta; Andrew Green, Northeast Georgia Medical Center, Gainesville, GA; Santiago González-Santiago, Hospital San Pedro de Alcántara, Cáceres; Isabel Bover, Hospital Son Llàtzer, Palma; Begoña Graña Suárez, University Hospital A Coruña, Sergas, Spain; Philippe Huot-Marchand and Yann Bourhis, Mapi Real World Evidence, Lyon, France; Sudeep Karve, AstraZeneca, Gaithersburg, MD; and Christopher Blakeley, AstraZeneca, Cambridge, United Kingdom.
Andrew GreenNicoletta Colombo, University of Milan-Bicocca; Nicoletta Colombo, Istituto Europeo di Oncologia, Milan; Giovanni Scambia, Università Cattolica del Sacro Cuore di Roma, Rome; Sandro Pignata, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G Pascale IRCCS, Naples, Italy; Gloria Huang, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx; Eva Chalas, Winthrop University Hospital, Mineola, NY; James Fiorica, Sarasota Memorial Hospital, Sarasota, FL; Linda Van Le, University of North Carolina School of Medicine, Chapel Hill, NC; Sharad Ghamande, The Georgia Cancer Center at Augusta University, Augusta; Andrew Green, Northeast Georgia Medical Center, Gainesville, GA; Santiago González-Santiago, Hospital San Pedro de Alcántara, Cáceres; Isabel Bover, Hospital Son Llàtzer, Palma; Begoña Graña Suárez, University Hospital A Coruña, Sergas, Spain; Philippe Huot-Marchand and Yann Bourhis, Mapi Real World Evidence, Lyon, France; Sudeep Karve, AstraZeneca, Gaithersburg, MD; and Christopher Blakeley, AstraZeneca, Cambridge, United Kingdom.
Philippe Huot-MarchandNicoletta Colombo, University of Milan-Bicocca; Nicoletta Colombo, Istituto Europeo di Oncologia, Milan; Giovanni Scambia, Università Cattolica del Sacro Cuore di Roma, Rome; Sandro Pignata, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G Pascale IRCCS, Naples, Italy; Gloria Huang, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx; Eva Chalas, Winthrop University Hospital, Mineola, NY; James Fiorica, Sarasota Memorial Hospital, Sarasota, FL; Linda Van Le, University of North Carolina School of Medicine, Chapel Hill, NC; Sharad Ghamande, The Georgia Cancer Center at Augusta University, Augusta; Andrew Green, Northeast Georgia Medical Center, Gainesville, GA; Santiago González-Santiago, Hospital San Pedro de Alcántara, Cáceres; Isabel Bover, Hospital Son Llàtzer, Palma; Begoña Graña Suárez, University Hospital A Coruña, Sergas, Spain; Philippe Huot-Marchand and Yann Bourhis, Mapi Real World Evidence, Lyon, France; Sudeep Karve, AstraZeneca, Gaithersburg, MD; and Christopher Blakeley, AstraZeneca, Cambridge, United Kingdom.
Yann BourhisNicoletta Colombo, University of Milan-Bicocca; Nicoletta Colombo, Istituto Europeo di Oncologia, Milan; Giovanni Scambia, Università Cattolica del Sacro Cuore di Roma, Rome; Sandro Pignata, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G Pascale IRCCS, Naples, Italy; Gloria Huang, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx; Eva Chalas, Winthrop University Hospital, Mineola, NY; James Fiorica, Sarasota Memorial Hospital, Sarasota, FL; Linda Van Le, University of North Carolina School of Medicine, Chapel Hill, NC; Sharad Ghamande, The Georgia Cancer Center at Augusta University, Augusta; Andrew Green, Northeast Georgia Medical Center, Gainesville, GA; Santiago González-Santiago, Hospital San Pedro de Alcántara, Cáceres; Isabel Bover, Hospital Son Llàtzer, Palma; Begoña Graña Suárez, University Hospital A Coruña, Sergas, Spain; Philippe Huot-Marchand and Yann Bourhis, Mapi Real World Evidence, Lyon, France; Sudeep Karve, AstraZeneca, Gaithersburg, MD; and Christopher Blakeley, AstraZeneca, Cambridge, United Kingdom.
Sudeep KarveNicoletta Colombo, University of Milan-Bicocca; Nicoletta Colombo, Istituto Europeo di Oncologia, Milan; Giovanni Scambia, Università Cattolica del Sacro Cuore di Roma, Rome; Sandro Pignata, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G Pascale IRCCS, Naples, Italy; Gloria Huang, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx; Eva Chalas, Winthrop University Hospital, Mineola, NY; James Fiorica, Sarasota Memorial Hospital, Sarasota, FL; Linda Van Le, University of North Carolina School of Medicine, Chapel Hill, NC; Sharad Ghamande, The Georgia Cancer Center at Augusta University, Augusta; Andrew Green, Northeast Georgia Medical Center, Gainesville, GA; Santiago González-Santiago, Hospital San Pedro de Alcántara, Cáceres; Isabel Bover, Hospital Son Llàtzer, Palma; Begoña Graña Suárez, University Hospital A Coruña, Sergas, Spain; Philippe Huot-Marchand and Yann Bourhis, Mapi Real World Evidence, Lyon, France; Sudeep Karve, AstraZeneca, Gaithersburg, MD; and Christopher Blakeley, AstraZeneca, Cambridge, United Kingdom.
Christopher BlakeleyNicoletta Colombo, University of Milan-Bicocca; Nicoletta Colombo, Istituto Europeo di Oncologia, Milan; Giovanni Scambia, Università Cattolica del Sacro Cuore di Roma, Rome; Sandro Pignata, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G Pascale IRCCS, Naples, Italy; Gloria Huang, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx; Eva Chalas, Winthrop University Hospital, Mineola, NY; James Fiorica, Sarasota Memorial Hospital, Sarasota, FL; Linda Van Le, University of North Carolina School of Medicine, Chapel Hill, NC; Sharad Ghamande, The Georgia Cancer Center at Augusta University, Augusta; Andrew Green, Northeast Georgia Medical Center, Gainesville, GA; Santiago González-Santiago, Hospital San Pedro de Alcántara, Cáceres; Isabel Bover, Hospital Son Llàtzer, Palma; Begoña Graña Suárez, University Hospital A Coruña, Sergas, Spain; Philippe Huot-Marchand and Yann Bourhis, Mapi Real World Evidence, Lyon, France; Sudeep Karve, AstraZeneca, Gaithersburg, MD; and Christopher Blakeley, AstraZeneca, Cambridge, United Kingdom.
Università Cattolica del Sacro Cuore · IT
Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5MNCI NIH HHS P30 CA016086
Abstract
Purpose There is a growing demand for BRCA1/ 2 mutation ( BRCAm) testing in patients with ovarian cancer; however, the limited number of genetic counselors presents a potential barrier. To facilitate more widespread BRCAm testing in ovarian cancer, pretest counseling by the oncology team could shorten testing turnaround times and ease the pressure on genetic counselors. Patients and Methods The prospective, observational Evaluating a Streamlined Onco-genetic BRCA Testing and Counseling Model Among Patients With Ovarian Cancer (ENGAGE) study evaluated a streamlined, oncologist-led BRCAm testing pathway. The analysis population comprised 700 patients with ovarian cancer at 26 sites in the United States, Italy, and Spain. The primary objectives were to assess turnaround time and, using questionnaires, to evaluate stakeholder satisfaction (patients, oncologists, and geneticists or genetic counselors) with the oncologist-led BRCAm testing pathway. Results The median overall turnaround time was 9.1 weeks (range, 0.9 to 37.1 weeks), with median turnaround times in the United States, Italy, and Spain of 4.1 weeks (range, 0.9 to 37.1 weeks), 20.4 weeks (range, 2.9 to 35.4 weeks), and 12.0 weeks (range, 2.0 to 36.7 weeks), respectively. Patient satisfaction with the oncologist-led BRCAm testing pathway was high, with > 99% of patients expressing satisfaction with pre- and post- BRCAm test counseling. Oncologist satisfaction with the BRCAm testing pathway was also high, with > 80% agreeing that the process for performing BRCAm testing worked well and that counseling patients on BRCAm testing was an efficient use of their time. Oncologists expressed higher levels of satisfaction with the BRCAm testing pathway than did geneticists or genetic counselors. Conclusion The results of the ENGAGE study demonstrate that an oncologist-led BRCAm testing process is feasible in ovarian cancer. Development of local BRCAm testing guidelines similar to the one used in this study could allow faster treatment decisions and better use of resources in the management of patients with ovarian cancer.
Indexed as
CounselingGenetic TestingOncologistsBRCA1 ProteinBRCA2 ProteinFemaleHumansItalyMiddle AgedMutationOvarian NeoplasmsProgram EvaluationProspective StudiesSpainSurveys and QuestionnairesUnited StatesBRCA1 ProteinBRCA2 Protein
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.